UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial

European journal of neurology, 2014-02, Vol.21 (2), p.299-304

2014

Volltextzugriff (PDF)

Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury

Clinical chemistry and laboratory medicine, 2024-01, Vol.62 (2), p.322-331

2024

Volltextzugriff (PDF)

Changes to anti-JCV antibody levels in a Swedish national MS cohort

Journal of neurology, neurosurgery and psychiatry, 2013-11, Vol.84 (11), p.1199-1205

2013

Volltextzugriff (PDF)

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Neurology, 2020-10, Vol.95 (14), p.661-661

2020

Volltextzugriff (PDF)

Blood neurofilament light levels segregate treatment effects in multiple sclerosis

Neurology, 2020-03, Vol.94 (11), p.e1201

2020

Volltextzugriff (PDF)

Anti-JC Virus Antibody Titer Changes during Natalizumab Treatment in a Swedish MS Cohort (P02.139)

Neurology, 2012, Vol.78 (Meeting Abstracts 1), p.P02-P02.139

2012

Volltextzugriff (PDF)

Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy

Multiple sclerosis journal - experimental, translational and clinical, 2016-01, Vol.2, p.2055217316630008-2055217316630008

2016

Volltextzugriff (PDF)

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Multiple sclerosis, 2013-10, Vol.19 (11), p.1533-1538

2013

Volltextzugriff (PDF)

Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2 (S41.002)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.S41-S41.002

2012

Volltextzugriff (PDF)

Updated Incidence of Progressive Multifocal Leukoencephalopathy in Natalizumab-Treated Multiple Sclerosis Patients Stratified by Established Risk Factors (S41.001)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.S41-S41.001

2012

Volltextzugriff (PDF)

RESTORE Study: Effects of a 24-Week Natalizumab Treatment Interruption on Immune Parameters and Multiple Sclerosis Magnetic Resonance Imaging Disease Activity (P06.168)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.P06-P06.168

2012

Volltextzugriff (PDF)

Evaluation of the incidence of anti-JC virus antibodies in a cohort of natalizumab-treated patients

Inflammatory bowel diseases, 2011-01, Vol.17 (suppl_1), p.S36-S36

2011

Volltextzugriff (PDF)

Plasma neurofilament light levels segregate treatment effects: results from the IMSE studies with multiple disease modulatory drugs

MULTIPLE SCLEROSIS JOURNAL, 2018, Vol.24, p.72

2018

Volltextzugriff (PDF)

International multi-site analytical validation of the Simoa NF-light assay in human serum samples from multiple sclerosis patients

MULTIPLE SCLEROSIS JOURNAL, 2018, Vol.24, p.249

2018

Volltextzugriff (PDF)

Anti-JCV antibody titre changes during natalizumab treatment in a Swedish MS cohort

MULTIPLE SCLEROSIS JOURNAL, 2011, Vol.17, p.S450

2011

Volltextzugriff (PDF)

Prevalence of anti-JCV antibodies in a multi-national cohort of multiple sclerosis patients

MULTIPLE SCLEROSIS JOURNAL, 2011, Vol.17, p.S134

2011

Volltextzugriff (PDF)

Republic of Latvia Materials on International Law 2014

Baltic yearbook of international law, 2016-07, Vol.15 (1), p.408-441

2016

Volltextzugriff (PDF)

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

The New England journal of medicine, 2012-05, Vol.366 (20), p.1870-1880

2012

Volltextzugriff (PDF)

N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection

Nature communications, 2021-03, Vol.12 (1), p.1931-1931, Article 1931

2021

Volltextzugriff (PDF)

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

Annals of neurology, 2014-12, Vol.76 (6), p.802-812

2014

Volltextzugriff (PDF)

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis

Multiple sclerosis, 2020-11, Vol.26 (13), p.1691-1699

2020

Volltextzugriff (PDF)

Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice

Multiple sclerosis, 2023-02, Vol.29 (2), p.196-205

2023

Volltextzugriff (PDF)

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

Journal of clinical virology, 2013-06, Vol.57 (2), p.141-146

2013

Volltextzugriff (PDF)

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1

Annals of neurology, 2011-11, Vol.70 (5), p.742-750

2011

Volltextzugriff (PDF)

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring

Multiple sclerosis, 2021-09, Vol.27 (10), p.1497-1505

2021

Volltextzugriff (PDF)

1 – 25 von 120

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(80)

Publikationsform

Sprache

Englisch
(117)
Russisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial

Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury

Changes to anti-JCV antibody levels in a Swedish national MS cohort

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Blood neurofilament light levels segregate treatment effects in multiple sclerosis

Anti-JC Virus Antibody Titer Changes during Natalizumab Treatment in a Swedish MS Cohort (P02.139)

Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2 (S41.002)

Updated Incidence of Progressive Multifocal Leukoencephalopathy in Natalizumab-Treated Multiple Sclerosis Patients Stratified by Established Risk Factors (S41.001)

RESTORE Study: Effects of a 24-Week Natalizumab Treatment Interruption on Immune Parameters and Multiple Sclerosis Magnetic Resonance Imaging Disease Activity (P06.168)

Evaluation of the incidence of anti-JC virus antibodies in a cohort of natalizumab-treated patients

Plasma neurofilament light levels segregate treatment effects: results from the IMSE studies with multiple disease modulatory drugs

International multi-site analytical validation of the Simoa NF-light assay in human serum samples from multiple sclerosis patients

Anti-JCV antibody titre changes during natalizumab treatment in a Swedish MS cohort

Prevalence of anti-JCV antibodies in a multi-national cohort of multiple sclerosis patients

Republic of Latvia Materials on International Law 2014

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis

Serum neurofilament light levels in natalizumab-treated patients with multiple sclerosis who switch to extended interval dosing from every-4-week dosing in real-world clinical practice

A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring

Suchergebnisse filtern